Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Investor Presentation (September 2016)
42 slides from Niagen Bioscience's investor presentation, Sep 13, 2016
Slide 1: Investor Presentation
ChromaDex CONNECTION Investor Presentation
Slide 2: Disclaimers
Disclaimers Safe Harbor Bape ewe te scat ot neces ce ern seri hanna ein 7A saat ae ingeueann Senos de Sa oe mang won on eptclosoct.Forereincng tres ot beret ingen oy oa frend yd ann ers porometcenncrrty rene sae sete paestets as panei yor onoed so eoa foro reno porson aie eet uae rant th fei, premen
Slide 3: Key Statistics
379m relisitess Key Shore Pic (ob of 9/7/2016) $832. Markt Cop (os of 9/7/2016) S268 Statistics (aes en iin oT ‘Average Daily Volume (3 Mo) oe onde Sm opt nd Total Revenue Ingredients Revenue
Slide 4: ChromaDex Discovers, Acquires, & Develops Early-Stage Proprietary Ingredient Technologies
ChromaDex Discovers, Acquires, & Develops Early-Stage Proprietary Ingredient Technologies and Commercializes them in Multi-Billion-Dollar Consumer Markets is ire Discover novel, early-stage ingredient technologies, poeonteie iy ee sulting businesses (> ChromaDex us Exclusively conse arent trom ch in
Slide 5: ChromaDex's Unique Business Model Gives it First-mover Advantages
ChromaDex’'s Unique Business Model Gives it First-mover Advantages in Identifying Proprietary Ingredient Technologies Over 1500 Industry Customers from our reference eas and ei cy Over 250 University & Research Institute customers ESTEE LAUDER @ Stanfor rd sit Access to Research Act LO ¢ (S chromade
Slide 6: Current Portfolio of Five Proprietary Ingredients
Current Portfolio of Five Proprietary Ingredients ( NIAGEN ‘| © NIAGEN® is the first and only commercially available form of nicotinamide . riboside (NR), a highly effective NAD+ booster. + pTeroPure® Pterostilbene is a phytoalexin (plant defense system) found plerePure naturally in blueberries, whi
Slide 7: Lead Ingredient - NIAGEN
ead ngresient— NIAGEN. + NIAGEN® is the Ist and onl: ChromaDex launched NIAGEN® in May 201 3. Nicotinamide Riboside (NR) is a vitamin B3 metabolite found naturally in trace amounts of milk. + NIAGEN® is an innovative patent-protected ingredient shown to be superior in boosting levels ‘of the importa
Slide 8: NAD+ Deficiency
NAD+ Deficiency cellular metabolism. around NAD+ up-regulation. "Demonstrating that NR is an effective precursor to ineré NAD+ in humans has significant positive implications and may be a cornerstone to developing solutions to delay or reverse the effects of aging, obesity and disease.” Nobel Leorea
Slide 9: NIAGEN as a Platform Ingredient
NIAGEN.as a Platform Ingredient Status Geese OX< Oo
Slide 10: Functional Ingredient Consumer Adoption Model
Tech Adoptors Functional Ingredient Consumer Adoption Model “ eAlceamreresil aloe, f een | i 5 H ' ; z aan 1 1 5 ' 4 3 Ho ' d 5 ' ' S10 4 } 2 1 1 = 0 : q Fy ' ; 3 a0 ' ; 5 ' ; ii i 1 ' 4 mature time
Slide 11: NIAGEN
NITIAGEN |
Slide 12: Regulatory Update
Regulatory Update New Dietary Ingredient (NDI) + NDI-status opens the Achieving NDI status is notifications in FY 201 Re enerally Recognized as Safe (GRAS) + Auge just 15) 5%, 2016 The L to nicotinamide riboside (NAGE ith, 2016 Ch meee be used in food & beverage products oduct Currently working on o
Slide 13: Healthy Aging & Healthspan
Healthy Aging & He ected to a Science of Living Longer In recent years there has been an enormous increase in research studying the science of aging as well as descrit patio an of time and chr. otis vidaaielig the cia between aging and age-related diseases. The term “Healthspan” has been ie we spend
Slide 14: Age: A Major Underlying Factor in Disease
Age: A Major Underlying Factor in Disease ‘+ History has shown that age itself is the greatest risk for contracting nearly every major disease. Yet research has cues focused on the distinct diseases, rather than studying the correlation between age and disease. While “Aging” a disease, age underlays
Slide 15: Pharmaceutical Interest in Aging as a Disease
Pharmaceutical Interest in Aging as a Disease Calico UNITY Biotechnology : Google-backed life sciences compony founded by Artur Leiner, foreerchaltuor nd numerous diseases of aging. CEO of Genentech recently entered the space with ‘additional backing from AbbVie. Medicines are. designed te lengthen
Slide 16: Research Collaborations
N® m Research Collaborations wi More than 80 pre-clinical and clinical studies represents over $50 million of non-paid research for ChromaDex y= fi ‘he Unversy oF uxtverstryer Progeria BIRMINGHAM Pork HH scuoe Muoicat fecoaloletbliy hemotheropy Induced OUCIwine comity 1 Flore Nit Ss" UURWERSTY OF CA
Slide 17: ChromaDex Funded NR Clinical Study Summary
maDex Funded NR Clinical Study Summary Results of First Study In August 2015, initial results of the first human clinical study for the company's NIAGEN® branded nicotinamide riboside (NR) indicate that the study met its primary endpoint. The results demonstrated that a single dose of NR resulted in
Slide 18: Human Clinical Trials 2016 - 2017
uman Clinical Trials 2016 - 2017 IH - NHLBI for Obesity Related Inflammation - Immune 2) ChromaDex KGK Chronic Study — NAD metabolome 3) CU Boulder - Aging and Physiology 4 University of Washington- Human PK - Heart Failure Trial Birmingham - Sports Exercise Trial , Copenhagen- Obesity & Pre-Diabeti
Slide 19: Pharmaceutical Opportunities
harmaceutical Opportunities NIH Study Results of a study conducted by National Institutes of Health (NIH) in collaboration with ChromaDex published in Newbee 2014 sate that NR was effective at restoring NAD+ levels in mitochondria and rescuing phenotypes associated with a devastating accelerated agi
Slide 20: Patent Portfolio Controlling the NAD+ Precursor Space
Patent Portfolio Controlling the NAD+ Precursor Space ChromaDex owns or controls commercially viable compounds that can act as NAD+ Precursors, putting ChromaDex in the enviable position of “gatekeeper” to the entire NAD+ precursor category. * US 8106184: . a 8114626 81978 * US 8383086: © US7776326:
Slide 21: Ingredient Development Pipeline
Ingredient Development Pipeline Product Potential Benefits Projected Launch peline Product 1 2016 Pipeline Product 2 2017 ipeline Product 3 2017 peline Product 4 2018 Pipeline Product 5 2018 Pipeline Product 6 Glutathione Precursor/Muscle Mobility 2019 © chromadex bk O ¢ 0
Slide 22: ChromaDex is Following the Model of Other Ingredient Technology Companies
ChromaDex is F Ing redient Technology Compani Patented Vegetarian Omega-3 Ingredient Acquired by DSM for $1.088 in 2010 mega-3 eon _q_ Acquired by DSM for Microalgae CCN Fish Oll Omega-3 gs 50M in July 2012 Ingredients ae i Acquired by DSM for Pra Flavor fortitech oa $634M in 2012 senomyx Ingredient
Slide 23: Scientific Advisory Board
Bl chromapex @ © emberg Bremer SCIENTIFIC ADVISORY BOARD evdeker ‘Gemmon + ChromaDex established its fi + Nobel Laureate Professor Roger Kornberg joined as Chair + The other SAB members are: + Dr. Charles Brenner, Professor Dr. Rob Beudek S chromadex ry @ gf 0
Slide 24: ChromaDex Highlights
aDex Highlights f \ + Addressable Ingredient Market Opportunity: Over $4 Billion Dollars ( NIAGEN. + Ingredient Patent Portfolio includes NIAGEN®, pTeroPure®, PURENERGY ®, IMMULINA™, ple Pure and AnthOrigin™ which are all in their early stages of revenue recognition Q2 2016 ingredient sales growth c
Slide 25: Appendix
S ChromaDex. Appen Additional Com;
Slide 26: ChromaDex at a Glance
ChromaDex at a Glance Legacy Busine: EN. é i pler@Purée o, be. Largest phytochemical 4a PUREKEREY — Analytical testing of leader in catalog in the world products for identity, scenic & regulatory IMMULINA Over 5,000 se potency, contaminants & coniiting services Used for QA & R&D label claims * Acqui
Slide 27: Company Overview
aD rVlIEw * ChromaDex is an innovator of proprietary health, wellness, and nutritional ingredients that creates science-based solutions for dietary supplements, food and pecsiooeid skin care, sports nutrition, and pharmaceutical products. * As a result of our relationships with leading universities
Slide 28: Nicotinamide adenine dinucleotide (NAD+)
Y i “Nicotinamide adenine dinucleotide {NAB #) is a coenzyme found in all living « a Cellular NAD* concentrations during aging, and modulation on NAD* usage or production can Broiong health span) and life span. >
Slide 29: What is NAD+ and Why is it Essential
What is NAD+ and Why is it Essential 2 NAD* Role in Celutar Eneray Production Teoding 1o Hout improvement oon redox coenzyme in cellular metabolism! ? ADPribose polymerases (PARPS),sirtuins and cyclic ADPribose synthetases! . cell division necessitate NAD+ consuming activities and ongoing NAD+ synth
Slide 30: NAD+ Reverses Mitochondrial Dysfunction
NAD+ Reverses Mitochondrial Dysfunction * NR treatment significantly increased NAD+ in tissues with high mitochondria content. tochengnals0 (tative to vetcle group) * NR treatment significantly enhanced mitochondrial function and mitochondrial biogenesis. Cistae content fuahatoroic pos)
Slide 31: NAD+ and Mitochondrial Function Declines with Aging
NAD+ and Mitochondrial Function Declines with Aging Human Data ~ NAD+ levels de Mouse Data — Energy, mit NAD* (ng/mg protein) iramatically with age tivity, mitochondrial DNA population and integrity all decrease with age 7 ‘ r i: i a a & os 308 $519 : bol) gk He : : _ § gee E as : gene e? B oz Soz i
Slide 32: * source: Camo tall Metab 85887, ane 2012
* source: Camo tall Metab 15 85887, 6 ane 2012
Slide 33: pTeroPure is ChromaDex's Commercialized, IP-backed, Clinically-Studied Branded Pterostilbene
pTeroPure® is ChromaDex's Commercialized, IP-backed, Clinically-Studied Branded Pterostilbene Overview Superior bioavailability; 80% versus 20% 7 times longer half-life in the body Greater oral absorption and metabolic stability 2-4 times greater cellular uptake The only form of pterostilbene with G
Slide 34: pTeroPure Evaluated in a Phase 2/3 Clinical Study
pTeroPure® was Evaluated in a Phase 2/3 Clinical Study Which Showed Statistically Significant Results for its Ability to Lower Blood Pressure Participants in the high-dose pterostilbene group achieved significant reductions in blood pressure compared to placebo (7.8mm Hg systolic, 7.3mm Hg diastolic
Slide 35: Topical Pterostilbene Study
fopical Pterostilbene Study On April 3°, 2015 The University of Valencia and Green Molecular, S.L. published a study indicating that ene Prevented acute ultraviolet B radiation ("UVB"), radiation-induced inflammation and photoaging- Te sed_on these We are currently in advanced discussion the topical
Slide 36: PURENERGY is ChromaDex's Patent Protected and Clinically Studied Caffeine Ingredient
PUREN ® is ChromaDex'’s Patent Protected and Cinically Studied Caffeine engrediont Ue + Caffeine = Pung hen ple rePl Overview By cocrystallizin at least 6 hours!, PURENERGY® als high-sugor products. Should allow formulators of caffeinated energy products the opportunity to reduce the total amount of
Slide 37: PURENERGY Clinical Results - 2013
PURENERGY® Clinical Results - 2013 Results of Study PURENERGY® delivers clmost 30% more caffeine into the blood than ordinary caffeine. The rate of caffeine absorption is significantly slower with PURENERGY”, by about 30% as compared to ordinary caffeine The half-life of caffeine from PURENERGY” is
Slide 38: Statements of Operations
atements of Operations! ff ares mad tra ly 2, 2016 hy 42015 Sos, § resorses § r1s02351 Cost gsezese ‘6964005, rot _—1879900_ 490096 Operating expenses: Sols ara martng szeerss 1.225525, Research and devoopent tisres "200505 General ad admit Aas118___ 3608.40 ‘Operaungexpenoes 6,759,558 566.60 ‘Opera
Slide 39: Balance Sheets
uty 2, 2016 and ny 2, 2016 ores Prop expenses andcter assets “Total current assats Leased provements and Equipment sat (ne Noneuren Assets “Total stockhotders equity Balance Sheets! uty2, 2016 2.2016 ssmze $s ssi9er2 7032 01 Seq 8.73.0, aertt ase Weiss Bsa azo susenaTe 1785688 Tess 412995 3345.05, 3
Slide 40: Statements of Cash Flows
iE canogeenge Period ‘Cash Ending of Chromadex &§§ © & OF atements of Cash Flows! income (oss) tone cash sortase 1,494,731 '74'509) (5.700) in operating activities (2.987.387 (497.176) iment (120 (199,162) 195,000 (2.500 in investing activites, (426201) 16182) 15601 Te pena oa — s9vance cost 2.85) a
Slide 41: Non-GAAP Presentation Reconciliation
Non-GAAP Presentation Reconciliation! Consoidted Statements of Operations, Adjusted EBITDA cling Interest, Tat, Depreciation, Amortization and Share based Compensation (Non GAAP Presntion) For the 3Month ul. 2,208 Consoldted Statements of Operations (Us caap) Fe Pe ul. 2, 2016 2nd Ju 4 2015 For the
Slide 42: Contact Information
Contact Information Vy ChromaDex Corporation 10005 Muirlands Blvd., Suite G Irvine, CA 92618 hee +1-949-419-0288 4+1-949- ae 0294 hromad ‘Andrew Johnson Director of Investor Relations Phone: +1-949- oe oe andrewi@chromai Sctrompex bf O